桑贝保金汤治疗小儿咳嗽变异性哮喘及对肺功能、总IgE的影响

发布时间：2018-08-07 17:03

【摘要】：目的：观察自拟中药汤剂桑贝保金汤加减治疗小儿咳嗽变异性哮喘的临床疗效及对肺功能、血清总IgE的影响。方法：本研究依据纳入标准筛选符合咳嗽变异性哮喘诊断的3-14岁患儿，共80例，随机分成试验组40例和对照组40例。试验组服用桑贝保金汤，，并随证加减，对照组口服酮替芬和氨茶碱片，疗程均为28天。观察两组治疗前后患儿的临床综合改善率、中医单项症状变化情况以及肺功能和血清总IgE水平的改变，以评价药物的有效性。试验前后化验血、尿、便常规、肝、肾功能，并观察试验期间有无不良反应发生，以评价药物的安全性。结果： 1．试验组桑贝保金汤对咳嗽变异性哮喘的显效率为76.9%,对照组显效率为45.0%，两组比较有统计学差异(P＜0.05)。在两组患儿单项症状情况变化的比较方面，试验组咳嗽、咽痒症状的显效率分别为84.6%、71.9%，对照组分别为60.0%、55.0%，试验组优于对照组(P＜0.05)，而咯痰、气促症状的显效率两组相比，无显著性差异（P＞0.05）。在改善肺功能方面，经治疗后两组患儿肺功能指标有最大通气量(MVV)、第1秒用力呼气量(FEV1)、50％用力肺活量时流速(Vmax50)、最大呼气流速(PEF)绝对值都得以显著改善，但试验组优于对照组(P＜0.05)。在对血清总IgE水平的影响方面，两组治疗后血清总IgE水平与同组治疗前比较，P＜0.05；试验组治疗后与对照组治疗后相比，P＜0.05，存在统计学差异。 2．本临床研究过程中所有患儿未发生明显不良反应，按照安全性评价标准认为桑贝保金汤具有良好的安全性。结论：桑贝保金汤对小儿咳嗽变异性哮喘有显著的临床疗效，可明显提高咳嗽变异性哮喘患儿的肺功能，降低咳嗽变异性哮喘患儿血清总IgE水平，同时具有良好安全性。
[Abstract]:Objective: to observe the clinical effect of Sangbei Baojin decoction on cough variant asthma in children and its effect on lung function and serum total IgE. Methods: according to the inclusive criteria, 80 children aged 3 to 14 years with cough variant asthma were randomly divided into two groups: the experimental group (n = 40) and the control group (n = 40). The experimental group was treated with Sanbiebaojin decoction, and the control group was treated with ketotifen and aminophylline tablets for 28 days. In order to evaluate the effectiveness of drugs, the clinical comprehensive improvement rate, the changes of individual symptoms of TCM and the changes of pulmonary function and serum total IgE levels were observed before and after treatment in the two groups. Before and after the test, blood, urine, stool routine, liver, renal function, and observed the adverse reactions during the trial to evaluate the safety of drugs. Results: 1. The effective rate of Sangbei Baojin decoction on cough variant asthma was 76.9 in the trial group and 45.0 in the control group. There was significant difference between the two groups (P < 0.05). In the comparison of the changes of individual symptoms between the two groups, the marked effective rates of cough and pharyngotic symptoms in the trial group were 84.61.90 and 60.055.0, respectively. The experimental group was superior to the control group (P < 0.05), but the effective rate of expectoration and shortness of breath was higher than that of the control group, and the effective rate of the symptoms of sputum and shortness of breath was higher in the experimental group than that in the control group (P < 0.05). There was no significant difference (P > 0.05). In terms of improving pulmonary function, after treatment, the pulmonary function indexes of the two groups were maximal ventilation volume (MVV), forced expiratory volume (FEV1) of 50% forced vital capacity (Vmax50), and the absolute value of (PEF) of maximal expiratory flow (PEF) were significantly improved. But the experimental group was superior to the control group (P < 0.05). In terms of the effect on serum total IgE level, the serum total IgE level after treatment in the two groups was significantly lower than that in the same group before treatment (P < 0.05). Compared with the control group, there was a statistical difference between the experimental group and the control group (P < 0.05). 2. In this clinical study, no significant adverse reactions occurred in all the children. According to the safety evaluation standard, it is considered that Sambai Baojin decoction has good safety. Conclusion: Sangbei Baojin decoction has a significant clinical effect on children with cough variant asthma, it can obviously improve the lung function of children with cough variant asthma, and reduce the total serum IgE level of children with cough variant asthma. At the same time, it has good safety.
【学位授予单位】：辽宁中医药大学
【学位级别】：硕士
【学位授予年份】：2012
【分类号】：R272

【参考文献】